Product DescriptionCamostat Mesylate, Purified Small Molecule, suitable to Neutralize.
Application(s)Neutralize
Application DetailsTrypsin-like protease inhibitor. Reversibly inhibits airway epithelial sodium channel (ENaC) function (IC50 = 50 nM). Inhibits the production of TNF-alpha and monocyte chemoattractant protein-1 (MCP-1) by monocytes and disrupts proliferation of pancreatic stellate cells in a rat model of pancreatic fibrosis.
TargetCamostat Mesylate
Target Host SpeciesSpecies Independent
Purity Description>98% by HPLC; NMR (Conforms)
Purity %> 98%
FormatDry powder; Off-white powder
Reconstitution InstructionsSoluble in water or DMSO. May be dissolved in DMSO up to 50 mg/mL, or water (50 mg/mL)
Storage InstructionsStore desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month. Prevent multiple freeze-thaw cycles.
Batch NumberPlease see item label.
Expiration DateStore desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month. Prevent multiple freeze-thaw cycles.
Alternative NamesCamostat Methanesulfonate;Camostat (mesylate); FOY 305; FOY-305; Foipan; CAS 59721-29-8
Scientific BackgroundPharmacology: A serine protease inhibitor inhibiting plasmin, kallikrein, thrombin as well as trypsin, which attenuates pancreatic fibrosis (1). Reduces weight gain and improves metabolism in obese rodent models (2). In clinical use (in Japan) for pancreatitis (3). Inhibits influenza virus replication in human tracheal epithelial cells (4). Reduces infection of Calu-3 lung cells by SARS-CoV-2 (responsible for COVID-19) via inhibition of the serine protease TMPRSS2 required for viral spike protein priming (5). PubChem CID: 5284360
Product is sold for research use only. Not for human therapeutic use or for medicinal purposes.
General ReferencesJ Gibo et al. Lab. Invest. 2005 85:75 K Albarazanji et al. Am. J. Physiol. Gastrointest. Liver Physiol. 2019 316:G653 M Ueda et al. Nephron 2015 129:223 M Yamaya et al. Pulm. Pharmacol. Ther. 2015 33:66